Key result
Dlk1 suppresses cardiac fibroblast differentiation and myocardial fibrosis via TGFβ/Smad-3 pathway inhibition.
Why the study?
There is currently no information on the role of delta-like homologue 1 (Dlk1) in the regulation of the fibrotic response in myocardial fibrosis.
Dlk1 acts as an inhibitor of cardiac fibroblast-to-myofibroblast differentiation by interfering with TGFβ/Smad-3 signalling, highlighting its potential as a therapeutic target for myocardial fibrosis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Dlk1 as antifibrotic target; leaves open translation to human myocardial fibrosis.
AIMS: Myocardial fibrosis is associated with profound changes in ventricular architecture and geometry, resulting in diminished cardiac function. There is currently no information on the role of the delta-like homologue 1 (Dlk1) in the regulation of the fibrotic response. Here, we investigated whether Dlk1 is involved in cardiac fibroblast-to-myofibroblast differentiation and regulates myocardial fibrosis and explored the molecular mechanism underpinning its effects in this process. METHODS AND RESULTS: Using Dlk1-knockout mice and adenoviral gene delivery, we demonstrate that overexpression of Dlk1 in cardio-fibroblasts resulted in inhibition of fibroblast proliferation and differentiation into myofibroblasts. This process is mediated by TGF-β1 signalling, since isolated fibroblasts lacking Dlk1 exhibited a higher activation of the TGF-β1/Smad-3 pathway at baseline, leading to an earlier acquisition of a myofibroblast phenotype. Likewise, Dlk1-null mice displayed increased TGF-β1/Smad3 cardiac activity, resulting in infiltration/accumulation of myofibroblasts, induction and deposition of extra-domain A-fibronectin isoform and collagen, and activation of pro-fibrotic markers. Furthermore, these profibrotic events were associated with disrupted myofibril integrity, myocyte hypertrophy, and cardiac dysfunction. Interestingly, Dlk1 expression was down-regulated in ischaemic human and porcine heart tissues. Mechanistically, miR-370 mediated Dlk1's regulation of cardiac fibroblast-myofibroblast differentiation by directly targeting TGFβ-R2/Smad-3 signalling, while the Dlk1 canonical target, Notch pathway, does not seem to play a role in this process. CONCLUSION: These findings are the first to demonstrate an inhibitory role of Dlk1 of cardiac fibroblast-to-myofibroblast differentiation by interfering with TGFβ/Smad-3 signalling in the myocardium. Given the deleterious effects of continuous activation of this pathway, we propose Dlk1 as a new potential candidate for therapy in cases where aberrant TGFβ signalling leads to chronic fibrosis.
No takes yet. Share an insight, caveat, or question.
Rodriguez et al. (2018) studied Myocardial fibrosis. Dlk1 deletion or overexpression vs. Wild-type or baseline was evaluated on Cardiac fibroblast-to-myofibroblast differentiation and myocardial fibrosis. Dlk1 inhibits cardiac fibroblast-to-myofibroblast differentiation and myocardial fibrosis by interfering with TGFβ/Smad-3 signalling, while its deletion accelerates these profibrotic events.
Synapse has enriched 10 related papers. Consider them for comparative context: